HK1170166A1 - Pharmaceutical composition for improving solubility of prasugrel and its preparation method - Google Patents

Pharmaceutical composition for improving solubility of prasugrel and its preparation method

Info

Publication number
HK1170166A1
HK1170166A1 HK12110932.6A HK12110932A HK1170166A1 HK 1170166 A1 HK1170166 A1 HK 1170166A1 HK 12110932 A HK12110932 A HK 12110932A HK 1170166 A1 HK1170166 A1 HK 1170166A1
Authority
HK
Hong Kong
Prior art keywords
prasugrel
preparation
pharmaceutical composition
improving solubility
solubility
Prior art date
Application number
HK12110932.6A
Other languages
English (en)
Chinese (zh)
Inventor
岑均達
張春紅
張起
吕愛鋒
Original Assignee
孫遠 江蘇省連雲港市
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 孫遠 江蘇省連雲港市 filed Critical 孫遠 江蘇省連雲港市
Publication of HK1170166A1 publication Critical patent/HK1170166A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK12110932.6A 2010-04-27 2012-10-31 Pharmaceutical composition for improving solubility of prasugrel and its preparation method HK1170166A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2010101586695A CN102232949A (zh) 2010-04-27 2010-04-27 提高药物溶出度的组合物及其制备方法
PCT/CN2011/073162 WO2011134369A1 (zh) 2010-04-27 2011-04-22 提高普拉格雷溶出度的药物组合物及其制备方法

Publications (1)

Publication Number Publication Date
HK1170166A1 true HK1170166A1 (en) 2013-02-22

Family

ID=44860861

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12110932.6A HK1170166A1 (en) 2010-04-27 2012-10-31 Pharmaceutical composition for improving solubility of prasugrel and its preparation method

Country Status (6)

Country Link
US (1) US9050328B2 (de)
EP (1) EP2564847B1 (de)
JP (1) JP5887040B2 (de)
CN (2) CN102232949A (de)
HK (1) HK1170166A1 (de)
WO (1) WO2011134369A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104800210B (zh) 2007-04-27 2019-08-06 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
KR101743591B1 (ko) 2009-05-13 2017-06-20 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
RU2013135445A (ru) 2010-12-31 2015-02-10 Сэнт-Гобэн Керамикс Энд Пластикс, Инк. Абразивное изделие (варианты) и способ его формования
CN102675338A (zh) * 2011-03-11 2012-09-19 上海现代制药股份有限公司 微粉化普拉格雷及其药用组合物
EP2726248B1 (de) 2011-06-30 2019-06-19 Saint-Gobain Ceramics & Plastics, Inc. Flüssigphasengesinterte abrasive siliciumcarbidpartikel
CN108262695A (zh) 2011-06-30 2018-07-10 圣戈本陶瓷及塑料股份有限公司 包括氮化硅磨粒的磨料制品
JP5802336B2 (ja) 2011-09-26 2015-10-28 サン−ゴバン セラミックス アンド プラスティクス，インコーポレイティド 研磨粒子材料を含む研磨製品、研磨粒子材料を使用する研磨布紙および形成方法
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
SI2797416T1 (sl) 2011-12-28 2017-12-29 Global Blood Therapeutics, Inc. Substituirane spojine benzaldehida in metode njihove uporabe pri povečanju oksigenacije tkiva
EP2797716B1 (de) 2011-12-30 2021-02-17 Saint-Gobain Ceramics & Plastics, Inc. Zusammengesetzte geformte schleifpartikel und verfahren zu ihrer herstellung
BR112014016159A8 (pt) 2011-12-30 2017-07-04 Saint Gobain Ceramics formação de partículas abrasivas moldadas
EP3517245B1 (de) 2011-12-30 2023-12-13 Saint-Gobain Ceramics & Plastics Inc. Geformte schleifpartikel und verfahren zu ihrer herstellung
CA2860755C (en) 2012-01-10 2018-01-30 Saint-Gobain Ceramics & Plastics, Inc. Abrasive particles having complex shapes and methods of forming same
US8840696B2 (en) 2012-01-10 2014-09-23 Saint-Gobain Ceramics & Plastics, Inc. Abrasive particles having particular shapes and methods of forming such particles
EP2830829B1 (de) 2012-03-30 2018-01-10 Saint-Gobain Abrasives, Inc. Schleifmittel mit fibrillierten fasern
KR20150020199A (ko) 2012-05-23 2015-02-25 생-고뱅 세라믹스 앤드 플라스틱스, 인코포레이티드 형상화 연마입자들 및 이의 형성방법
EP2866977B8 (de) 2012-06-29 2023-01-18 Saint-Gobain Ceramics & Plastics, Inc. Schleifpartikel mit besonderen formen und verfahren zur formung solcher partikel
CN102764264A (zh) * 2012-07-25 2012-11-07 杭州和泽医药科技有限公司 一种具高溶出度的塞来昔布固体组合物、制备方法及应用
CN104822494B (zh) 2012-10-15 2017-11-28 圣戈班磨料磨具有限公司 具有特定形状的磨粒以及形成这种粒子的方法
CN103012427B (zh) * 2012-11-26 2015-07-08 天津大学 一种普拉格雷盐酸盐乙醇溶剂化物及其制备方法
CN103893137B (zh) * 2012-12-27 2017-09-29 上海创诺制药有限公司 一种制备普拉格雷片剂的方法
JP2016503731A (ja) 2012-12-31 2016-02-08 サン−ゴバン セラミックス アンド プラスティクス，インコーポレイティド 粒子材料およびその形成方法
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
EP2968299B1 (de) 2013-03-15 2021-01-20 Global Blood Therapeutics, Inc. Verbindungen und verwendungen davon zur modulation von hämoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
BR112015021982B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008721A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2907372C (en) 2013-03-29 2017-12-12 Saint-Gobain Abrasives, Inc. Abrasive particles having particular shapes and methods of forming such particles
TW201502263A (zh) 2013-06-28 2015-01-16 Saint Gobain Ceramics 包含成形研磨粒子之研磨物品
WO2015031284A1 (en) * 2013-08-26 2015-03-05 Global Blood Therapeutics, Inc. Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s)
CN103467484B (zh) * 2013-08-30 2014-11-19 海南灵康制药有限公司 一种微粉化的普拉格雷及其盐的化合物及药物组合物
CN104434805B (zh) * 2013-09-22 2017-09-29 成都盛迪医药有限公司 一种替格瑞洛固体分散体及其制备方法
WO2015048768A1 (en) 2013-09-30 2015-04-02 Saint-Gobain Ceramics & Plastics, Inc. Shaped abrasive particles and methods of forming same
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
JP6290428B2 (ja) 2013-12-31 2018-03-07 サンーゴバン アブレイシブズ，インコーポレイティド 成形研磨粒子を含む研磨物品
US9771507B2 (en) 2014-01-31 2017-09-26 Saint-Gobain Ceramics & Plastics, Inc. Shaped abrasive particle including dopant material and method of forming same
CN114181195A (zh) 2014-02-07 2022-03-15 全球血液疗法股份有限公司 一种化合物的结晶多晶型物
WO2015160854A1 (en) 2014-04-14 2015-10-22 Saint-Gobain Ceramics & Plastics, Inc. Abrasive article including shaped abrasive particles
JP6484647B2 (ja) 2014-04-14 2019-03-13 サン−ゴバン セラミックス アンド プラスティクス，インコーポレイティド 成形研磨粒子を含む研磨物品
US9902045B2 (en) 2014-05-30 2018-02-27 Saint-Gobain Abrasives, Inc. Method of using an abrasive article including shaped abrasive particles
US9914864B2 (en) 2014-12-23 2018-03-13 Saint-Gobain Ceramics & Plastics, Inc. Shaped abrasive particles and method of forming same
US9707529B2 (en) 2014-12-23 2017-07-18 Saint-Gobain Ceramics & Plastics, Inc. Composite shaped abrasive particles and method of forming same
US9676981B2 (en) 2014-12-24 2017-06-13 Saint-Gobain Ceramics & Plastics, Inc. Shaped abrasive particle fractions and method of forming same
KR101561406B1 (ko) * 2015-02-02 2015-10-16 환인제약 주식회사 두타스테라이드 함유 고체 분산체 및 이를 포함하는 조성물
WO2016161157A1 (en) 2015-03-31 2016-10-06 Saint-Gobain Abrasives, Inc. Fixed abrasive articles and methods of forming same
TWI634200B (zh) 2015-03-31 2018-09-01 聖高拜磨料有限公司 固定磨料物品及其形成方法
CA3118239A1 (en) 2015-06-11 2016-12-15 Saint-Gobain Ceramics & Plastics, Inc. Abrasive article including shaped abrasive particles
EP3156049A1 (de) 2015-10-15 2017-04-19 Alembic Pharmaceuticals Limited Pharmazeutische zusammensetzung von prasugrel
SG11201804647TA (en) 2015-12-04 2018-06-28 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN109415615A (zh) 2016-05-10 2019-03-01 圣戈本陶瓷及塑料股份有限公司 磨料颗粒及其形成方法
US20170335155A1 (en) 2016-05-10 2017-11-23 Saint-Gobain Ceramics & Plastics, Inc. Abrasive particles and methods of forming same
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
EP4349896A3 (de) 2016-09-29 2024-06-12 Saint-Gobain Abrasives, Inc. Feste schleifartikel und verfahren zur formung davon
GR1009230B (el) * 2016-10-12 2018-02-22 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βεσυλικη πρασουγρελη
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2018073437A1 (en) * 2016-10-21 2018-04-26 Laboratorios Lesvi, Sl Pharmaceutical formulations of prasugrel and processes for the preparation thereof
WO2018082557A1 (en) 2016-11-02 2018-05-11 Sunshine Lake Pharma Co., Ltd. Vilazodone inclusion complexes, compositions and preparation thereof
US10563105B2 (en) 2017-01-31 2020-02-18 Saint-Gobain Ceramics & Plastics, Inc. Abrasive article including shaped abrasive particles
US10759024B2 (en) 2017-01-31 2020-09-01 Saint-Gobain Ceramics & Plastics, Inc. Abrasive article including shaped abrasive particles
CN110719946B (zh) 2017-06-21 2022-07-15 圣戈本陶瓷及塑料股份有限公司 颗粒材料及其形成方法
CN110711180B (zh) * 2018-07-13 2022-03-29 武汉武药科技有限公司 一种替格瑞洛组合物及其制备方法
EP3820451B1 (de) 2018-07-13 2024-07-24 Council Of Scientific & Industrial Research Feste dispersion mit einer antikrebsverbindung mit verbesserter löslichkeit und wirksamkeit
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
EP4081609A4 (de) 2019-12-27 2024-06-05 Saint-Gobain Ceramics & Plastics Inc. Schleifartikel und verfahren zur formung davon
KR20220116556A (ko) 2019-12-27 2022-08-23 세인트-고바인 세라믹스 앤드 플라스틱스, 인크. 연마 물품 및 이의 형성 방법
JP7128543B2 (ja) 2020-12-25 2022-08-31 株式会社レーベン 冷凍庫

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1321192C (en) * 1988-04-20 1993-08-10 Abdul Majid Inclusion complexes of cyclodextrins by agglomeration
PL2007362T3 (pl) * 2006-04-04 2019-02-28 Kg Acquisition Llc Doustne postacie leku obejmujące czynnik przeciwpłytkowy i inhibitor kwasu
WO2008060394A2 (en) 2006-10-27 2008-05-22 Inova Diagnostics, Inc. Methods and assays for detecting gp73-specific autoantibodies
US20100062066A1 (en) * 2006-11-14 2010-03-11 Acusphere, Inc Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration
WO2008072534A1 (ja) * 2006-12-07 2008-06-19 Daiichi Sankyo Company, Limited マンニトール又は乳糖を含有する固形製剤
US20080166893A1 (en) 2007-01-08 2008-07-10 Jeong Soo Byun Low temperature oxide formation
CN104800210B (zh) * 2007-04-27 2019-08-06 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
CN101177430A (zh) * 2007-12-11 2008-05-14 鲁南制药集团股份有限公司 氢化吡啶衍生物及其盐的制备方法
CN101456864B (zh) * 2007-12-11 2011-04-13 鲁南制药集团股份有限公司 普拉格雷硫酸盐、组合物及其制备方法
CN101554378B (zh) * 2008-04-09 2011-01-12 鲁南制药集团股份有限公司 含有普拉格雷的药物组合物
JP2011529859A (ja) * 2008-08-02 2011-12-15 ルナン ファーマシューティカル グループ コーポレーション プラスグレル重硫酸塩及びその薬物組成物並びにその応用
EA024980B1 (ru) * 2009-02-17 2016-11-30 КРКА, д.д., НОВО МЕСТО Лекарственные формы, содержащие основание прасугреля или его фармацевтически приемлемые соли присоединения кислоты, и способы их приготовления
DE102009010159B4 (de) 2009-02-23 2015-12-03 Carl Zeiss Ag Vorrichtung und Verfahren zur Abstandsmessung
CN101579337A (zh) * 2009-02-25 2009-11-18 牛华英 氯吡格雷组合物及其制备方法
KR101743591B1 (ko) * 2009-05-13 2017-06-20 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
CN101633662A (zh) * 2009-07-30 2010-01-27 巢杰 普拉格雷的药用酸加成盐及其制备方法和药物应用
DE102009036646A1 (de) * 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon
EP2360159A1 (de) * 2010-02-11 2011-08-24 Ratiopharm GmbH Prasugrel in mikronisierter, kristalliner Form und pharmazeutische Zusammensetzung davon
EP2377520A1 (de) * 2010-03-24 2011-10-19 Ratiopharm GmbH Pharmazeutische Zusammensetzung des Prasugrels
CN101810611A (zh) * 2010-04-10 2010-08-25 山东新华制药股份有限公司 普拉格雷及其酸加成盐的环糊精包合物及其制备方法

Also Published As

Publication number Publication date
US20130045251A1 (en) 2013-02-21
EP2564847A4 (de) 2013-10-02
EP2564847A1 (de) 2013-03-06
CN102232949A (zh) 2011-11-09
JP2013525386A (ja) 2013-06-20
JP5887040B2 (ja) 2016-03-16
EP2564847B1 (de) 2016-11-23
US9050328B2 (en) 2015-06-09
CN102811718A (zh) 2012-12-05
WO2011134369A1 (zh) 2011-11-03
CN102811718B (zh) 2015-01-28

Similar Documents

Publication Publication Date Title
HK1170166A1 (en) Pharmaceutical composition for improving solubility of prasugrel and its preparation method
HK1250313A1 (zh) 穩定的藥物組合物和使用所述組合物的方法
HK1175947A1 (en) Pharmaceutical compositions and methods of making same
IL222199A0 (en) Process for preparation of dopo-derived compounds and compositions thereof
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
EP2623100A4 (de) Präparat zur verbesserung der löslichkeit eines schlecht löslichen arzneimittels
PL2413912T3 (pl) Preparaty farmaceutyczne zawierające pochodne nitrokatecholu oraz metody ich wytwarzania
EP2666471A4 (de) Pharmazeutische zusammensetzung für milz und leber und herstellungsverfahren dafür
ZA201403195B (en) Pharmaceutical compositions of hydrophobic camptothecin derivatives
IL225606A0 (en) A method for preparing an inactive supplement suitable for pharmaceutical use
PL2555787T3 (pl) Formulacja kurkuminy o zwiększonej biodostępności kurkuminy i sposób jej wytwarzania i traktowania
IL231505A0 (en) Pharmaceutical preparation and method for its production
EP2601200A4 (de) Präparat aus prasugrelhydrochlorid
HK1193050A1 (zh) 用於治療早泄的藥物組合物以及用於治療早泄的方法
EP2586430A4 (de) Pharmazeutische zusammensetzung mit verbesserter löslichkeit eines teilweise löslichen trizyklischen derivats
GB201002278D0 (en) composition and method of preparation
EP2634192A4 (de) Verfahren zur herstellung von fosamprenavir-derivaten und zwischenprodukten davon

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190420